Targets › ITGA4
10 programs from 10 companies in 52 trials: 19 Phase 2, 17 Phase 3, 11 Phase 4, 5 Phase 1; Immunology, Oncology, Neurology; next expected readout Dec 2026.
Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. (UniProt, P13612)
Open in Phaseline: the race on ITGA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Vedolizumab Integrin alpha-4/beta-7 inhibitor | ITGA4, ITGB7 | Phase 4 | Ulcerative Colitis; Crohn's Disease; Crohn's Disease (CD); Moderately to Severely Active Ulcerative Colitis … | May 2027 |
| The Cleveland Clinic | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 4 | Multiple Sclerosis, Relapsing-Remitting | Jul 2027 |
| Roche | Afimkibart Anti-integrin α4β7 monoclonal antibody | ITGA4, ITGB7, IL22RA1 | Phase 3 | Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis … | Dec 2026 |
| ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | RAB001 (LLP2A-Alendronate) LLP2A peptide targeting integrin alpha-4 beta-1 conjugated to alendronate | ITGA4 | Phase 2 | Osteonecrosis | Feb 2027 |
| Queen Mary University of London | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 2 | Multiple Sclerosis | Oct 2027 |
| Gilead Sciences | emvistegrast (GS-1427) α4 integrin antagonist | ITGA4 | Phase 2 | Ulcerative Colitis | Apr 2028 |
| University of Michigan Rogel Cancer Center | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | May 2028 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | MORF-057 Selective integrin α4β7 inhibitor | ITGA4, ITGB7 | Phase 2 | Inflammatory Bowel Diseases | Sep 2028 |
| First Affiliated Hospital of Zhejiang University | A-CAR028 Bispecific chimeric antigen receptor T-cell targeting CD33 and CLL-1 | CD33, ITGA4 | Phase 1 | Acute Myeloid Leukemia (AML) | Dec 2026 |
| 7 Hills Pharma | Alintegimod α4β7 integrin antagonist | ITGA4, ITGB7 | Phase 1 | Advanced Cancer | Dec 2027 |
Ulcerative Colitis (12) Moderately to Severely Active Ulcerative Colitis (5) Crohn's Disease (4) Moderately to Severely Active Crohns Disease (3) Crohn Disease (2) Acute Lymphoblastic Leukemia (2) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Inflammatory Bowel Diseases (2) Osteonecrosis (1) Crohn's Disease (CD) (1) Pouchitis (1)
small molecule (3), antibody (3), mixed (3), protein or peptide (1)
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. (1) Takeda (1) Roche (1) University of Michigan Rogel Cancer Center (1) Queen Mary University of London (1) Gilead Sciences (1) 7 Hills Pharma (1) The Cleveland Clinic (1) Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (1) First Affiliated Hospital of Zhejiang University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.